Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 Data validation
1.5 Data Sources
1.5.1 Primary
1.5.2 Secondary
1.5.2.1 Paid sources
1.5.2.2 Public sources
Chapter 2 Executive Summary
2.1 Global ophthalmology drugs industry 360º synopsis, 2018 – 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Therapeutic class trends
2.1.4 Indication trends
2.1.5 Route of administration trends
2.1.6 Product trends
2.1.7 Dosage form trends
2.1.8 Distribution channel trends
Chapter 3 Ophthalmology Drugs Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of eye disorders
3.2.1.2 Rising research and development pertaining to the development of novel drugs
3.2.1.3 Technological advances in diagnostic and treatment modalities
3.2.1.4 Increase in awareness of eye disorders
3.2.1.5 Growing geriatric population
3.2.1.6 Increasing focus on developing combination therapies
3.2.2 Industry pitfalls & challenges
3.2.2.1 Loss of patent protection for popular drugs
3.2.2.2 Lack of health insurance in the developing countries
3.3 Growth potential analysis
3.3.1 By therapeutic class
3.3.2 By indication
3.3.3 By route of administration
3.3.4 By product
3.3.5 By dosage form
3.3.6 By distribution channel
3.4 Regulatory landscape
3.4.1 U.S.
3.4.2 Europe
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis, 2023
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard, 2023
Chapter 5 Ophthalmology Drugs Market Size and Forecast, By Therapeutic Class, 2018-2032 (USD Million)
5.1 Key trends, by therapeutic class
5.2 Anti-VEGF agents
5.3 Anti-glaucoma drugs
5.3.1 Alpha agonist
5.3.2 Beta blockers
5.3.3 Prostaglandin analogs
5.3.4 Combined medication
5.3.5 Other anti-glaucoma drugs
5.4 Anti-inflammatory drugs
5.4.1 Steroids
5.4.2 NSAIDs
5.5 Anti-infective drugs
5.5.1 Anti-bacterial drugs
5.5.2 Anti-fungal drugs
5.5.3 Other anti-infective drugs
5.6 Anti-allergy drugs
5.7 Other therapeutic categories
Chapter 6 Ophthalmology Drugs Market Size and Forecast, By Indication, 2018-2032 (USD Million)
6.1 Key trends, by indication
6.2 Dry eye
6.3 Glaucoma
6.4 Infection/inflammation
6.5 Retinal disorders
6.5.1 Wet AMD
6.5.2 Dry AMD
6.5.3 Diabetic retinopathy
6.5.4 Other retinal disorders
6.6 Allergy
6.7 Uveitis
6.8 Myopia
6.9 Ptosis
6.10 FECD
6.11 Retinitis pigmentosa
6.12 Other indications
Chapter 7 Ophthalmology Drugs Market Size and Forecast, By Route of Administration, 2018-2032 (USD Million)
7.1 Key trends, by route of administration
7.2 Topical
7.3 Local ocular (intravitreal)
7.4 Other routes of administration
Chapter 8 Ophthalmology Drugs Market Size and Forecast, By Product, 2018-2032 (USD Million)
8.1 Key trends, by product
8.2 Prescription
8.3 OTC
Chapter 9 Ophthalmology Drugs Market Size and Forecast, By Dosage Form, 2018-2032 (USD Million)
9.1 Key trends, by dosage form
9.2 Eye drops
9.3 Capsules and tablets
9.4 Gels
9.5 Ointments
9.6 Injectables
9.7 Cream
9.8 Other dosage forms
Chapter 10 Ophthalmology Drugs Market Size and Forecast, By Distribution Channel, 2018-2032 (USD Million)
10.1 Key trends, by distribution channel
10.2 Hospital pharmacies
10.3 Retail pharmacies
10.4 Online pharmacies
Chapter 11 Ophthalmology Drugs Market Size and Forecast, By Region, 2018-2032 (USD Million)
11.1 Key trends, by region
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 France
11.3.4 Spain
11.3.5 Italy
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 South Korea
11.4.6 Rest of Asia Pacific
11.5 Latin America
11.5.1 Brazil
11.5.2 Mexico
11.5.3 Rest of Latin America
11.6 Midde East & Africa
11.6.1 South Africa
11.6.2 Saudi Arabia
11.6.3 Rest of Middle East & Africa
Chapter 12 Company Profiles
12.1 AbbVie, Inc.
12.2 Alcon Vision LLC
12.3 Bausch Health Companies, Inc.
12.4 Bayer AG
12.5 Coherus BioSciences
12.6 F. Hoffmann-La Roche Ltd.
12.7 Novartis AG
12.8 Pfizer, Inc.
12.9 Regeneron Pharmaceuticals, Inc.
12.10 Santen, Inc.
12.11 Sun Pharmaceutical Industries Ltd.
12.12 Teva Pharmaceutical Industries Ltd.
